General
Preferred name
VILOXAZINE
Synonyms
Emovit ()
Viloxazin ()
Viloxazine hydrochloride ()
SPN-812 ()
viloxazine ER, Supernus Pharmaceuticals ()
Viloxazine (hydrochloride) ()
Viloxazin (hydrochloride) ()
Emovit (hydrochloride) ()
Viloxazina ()
viloxazine ()
ICI 58,834 ()
Qelbree ()
ICI-58834 ()
Vivalan ()
Viloxazine hcl ()
P&D ID
PD009011
CAS
46817-91-8
35604-67-2
Tags
available
drug
Approved by
FDA
First approval
2021
Drug indication
Major depressive disorder
Attention deficit hyperactivity disorder
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Viloxazine is a selective noradrenaline reuptake inhibitor (NRI) with minimal inhibitory effect on the reuptake of 5-HT. It is also shown to upregulate the levels of GABA-B receptors in the rat frontal cortex. It is shown to form a complex with the human norepinephrine transporter (hNET) [A19788].; The S(-)-stereoisomer of viloxazine exhibits more potent pharmacological actions [A19789].
DESCPRITION A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.
DESCRIPTION Viloxazine was originally described as a selective norepinephrine reuptake inhibitor (NRI), principally based on its ability to potentiate noradrenergic effects. It also modulates 5-HT (serotonin) activity, via antagonistic activity at 5-HT2B and agonistic activity at 5-HT2C receptors, and it increases extracellular 5-HT levels in the prefrontal cortex (PFC) . Viloxazine's chemical structure is different from conventional tri- or tetra-cyclic antidepressants. The INN stipulates a racemic mixture of enantiomers. We show the structure without specified stereochemistry to represent the mixture. The hydrocholride salt (SPN-812) was progressed by Supernus Pharmaceuticals for attention deficit hyperactivity disorder (ADHD) in children and adults. (GtoPdb)
DESCRIPTION Viloxazine is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50= 0.26 ¦ÌM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 ¦ÌM) and agonizes 5-HT2C receptors (EC50= 32 ¦ÌM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD)[1][2][3].
PRICE 29
DESCRIPTION Viloxazine (Viloxazin) (Viloxazin) is a dual-action compound that functions as a norepinephrine reuptake inhibitor and exhibits potent agonistic activity towards 5-HT 2C receptors while acting as an antagonist for 5-HT 2B receptors, with respective potency values of EC 50 = 32 ??M and IC 50 = 27 ??M. Its primary mechanism of action involves the modulation of serotonergic and noradrenergic pathways. Viloxazine is commonly employed in depression research [1] [2].
DESCRIPTION Viloxazine hydrochloride is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50=0.26 ¦ÌM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 ¦ÌM) and agonizes 5-HT2C receptors (EC50=32 ¦ÌM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD)[1][2][3].
DESCRIPTION Viloxazine is a selective norepinephrine reuptake inhibitor with minimal inhibitory effect on the reuptake of 5-HT. It is indicated for the treatment of clinical depression. (Enamine Bioactive Compounds)
DESCRIPTION Viloxazine (Viloxazin) (Viloxazin) is a dual-action compound that functions as a norepinephrine reuptake inhibitor and exhibits potent agonistic activity towards 5-HT 2C receptors while acting as an antagonist for 5-HT 2B receptors, with respective potency values of EC 50 = 32 μM and IC 50 = 27 μM. Its primary mechanism of action involves the modulation of serotonergic and noradrenergic pathways. Viloxazine is commonly employed in depression research [1] [2]. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
17
ChEMBL Approved Drugs
CHEMBL306700
CHEMBL2106483
ChEMBL Drugs
CHEMBL306700
CHEMBL2106483
DrugBank
DB09185
DrugBank Approved Drugs
DB09185
DrugCentral
2820
DrugCentral Approved Drugs
2820
DrugMAP
DMTV7XH
DrugMatrix
Enamine Bioactive Compounds
EBC-06656
Enamine BioReference Compounds
Guide to Pharmacology
11502
Ki Database
Viloxazine
MedChem Express Bioactive Compound Library
HY-W380450
HY-125784
NCATS Inxight Approved Drugs
5I5Y2789ZF
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T60325
External IDs
46
Properties
(calculated by RDKit )
Molecular Weight
237.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
1
cLogP
1.45
TPSA
39.72
Fraction CSP3
0.54
Chiral centers
1.0
Largest ring
6.0
QED
0.84
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
5-HT Receptor
norepinephrine reuptake
5-HT2C
5-HT2B
Source data